Ligand Pharmaceuticals Incorporated
LGND
$213.21
-$5.77-2.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 779.41M | 733.52M | 664.52M | 245.02M | 208.90M |
| Total Receivables | 66.95M | 83.84M | 70.51M | 52.39M | 52.93M |
| Inventory | 13.27M | 9.13M | 11.90M | 15.49M | 14.61M |
| Prepaid Expenses | -- | -- | -- | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 5.80M | 5.79M | 6.99M | 40.04M | 32.87M |
| Total Current Assets | 865.42M | 832.27M | 753.92M | 352.95M | 309.32M |
|
|
|||||
| Total Current Assets | 865.42M | 832.27M | 753.92M | 352.95M | 309.32M |
| Net Property, Plant & Equipment | 10.28M | 7.22M | 11.08M | 11.62M | 10.49M |
| Long-term Investments | 101.54M | 101.54M | 101.54M | 101.54M | 101.54M |
| Goodwill | 101.54M | 101.54M | 101.54M | 101.54M | 101.54M |
| Total Other Intangibles | 217.34M | 225.44M | 233.54M | 250.13M | 258.39M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 218.25M | 226.21M | 227.98M | 221.45M | 214.79M |
| Total Assets | 1.53B | 1.56B | 1.48B | 948.60M | 905.44M |
|
|
|||||
| Total Accounts Payable | 5.26M | 3.24M | 3.68M | 8.58M | 5.37M |
| Total Accrued Expenses | 29.47M | 29.08M | 20.71M | 15.09M | 21.16M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 1.09M | 1.12M | 1.09M | 1.11M | 883.00K |
| Total Finance Division Other Current Liabilities | 4.85M | 4.01M | 5.06M | 39.95M | 31.27M |
| Total Other Current Liabilities | 4.85M | 4.01M | 5.06M | 39.95M | 31.27M |
| Total Current Liabilities | 40.67M | 37.45M | 30.54M | 64.73M | 58.68M |
|
|
|||||
| Total Current Liabilities | 40.67M | 37.45M | 30.54M | 64.73M | 58.68M |
| Long-Term Debt | 446.90M | 446.19M | 445.49M | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 3.99M | 4.23M | 4.42M | 4.63M | 3.57M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 43.23M | 55.56M | 46.15M | 50.71M | 47.65M |
| Total Liabilities | 534.78M | 543.43M | 526.60M | 120.08M | 109.90M |
|
|
|||||
| Common Stock & APIC | 397.19M | 400.67M | 362.63M | 358.66M | 340.56M |
| Retained Earnings | 594.74M | 608.09M | 578.22M | 461.38M | 456.53M |
| Treasury Stock & Other | 5.39M | 8.46M | 9.32M | 8.49M | -1.56M |
| Total Common Equity | 997.32M | 1.02B | 950.17M | 828.53M | 795.53M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 997.32M | 1.02B | 950.17M | 828.53M | 795.53M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 997.32M | 1.02B | 950.17M | 828.53M | 795.53M |
|
|
|||||